Long Shortz with Orthocell: Gateway to Asia open with Singapore market entry

Stockhead’s Sarah Hughan sits down with Orthocell’s (ASX:OCC) CEO and MD Paul Anderson to get the short end of the long story on the company’s latest news.

The company has received regulatory approval from the Health Sciences Authority in Singapore to start selling its nerve repair product, Remplir.

And in the September 24 quarter it achieved a second consecutive quarter of record revenue.

Tune in to hear Orthocell’s Paul Anderson on the Singapore market, the growth in sales, and more.

This video was developed in collaboration with Orthocell, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.